Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Authors
Beswick, PaulWahab, Ben
Honey, Mark A.
Paradowski, Michael
Jiang, Ke
Lochner, Martin
Murrell-Lagnado, Ruth D.
Thompson, Andrew J.
Issue Date
2019-06-24
Metadata
Show full item recordAbstract
Identifying novel small-molecule P2X1 and P2X4 ligands with sub-type specificity and high-affinity remains a pharmacological challenge. Here we use computational methods, electrophysiology and fluorescent microplate assays to screen for ligand candidates acting at these receptors. Modelling and docking identified 80 compounds for testing at P2X4 receptors, and 20 of these showed >50% inhibition in fluorescence-based assays, making them appealing for further SAR studies. Confirmation of activity by two-electrode voltage clamp, followed by their elaboration resulted in only minor improvements in potency, with the highest IC50 being 295 μM. Testing on P2X1 receptors, resulted in a series of biguanide compounds that yielded a maximum IC50 of 100 μM, but no consistent SAR could be found. Potencies of established antagonists gave expected results, although the measured potencies varied between techniques and no antagonism could be found for compounds such as paroxetine, carbamazepine, 9(10H)-acridanone, acridinol and phenoxazine-type heterocycles. This study highlights the challenge of identifying P2X4 and P2X1 ligands and suggests that a combination of complimentary approaches is needed if we are to be confident of ligand activities at these receptors.Citation
Beswick, P., Wahab, B., Honey, M. A., Paradowski, M., Jiang, K., Lochner, M., Murrell-Lagnado, R. D. and Thompson, A. J. (2019) A challenge finding P2X1 and P2X4 ligands, Neuropharmacology, 157 (October 2019), DOI: 10.1016/j.neuropharm.2019.107674Publisher
ElsevierJournal
NeuropharmacologyAdditional Links
https://www.sciencedirect.com/science/article/pii/S0028390819302345Type
Journal articleLanguage
enISSN
0028-3908Sponsors
The British Heart Foundation supported AJT (grant; PG/13/39/30293). RML was supported by EU COST Action BM1046.ae974a485f413a2113503eed53cd6c53
10.1016/j.neuropharm.2019.107674
Scopus Count
Collections
The following licence applies to the copyright and re-use of this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 United States